Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics, Inc. Schedule 13G/A reports that K2 HealthVentures Equity Trust LLC and its managing members, Parag Shah and Anup Arora, may be deemed to beneficially own 5,790,453 shares of Common Stock as of March 31, 2026. These shares represent approximately 3.1% of the class based on 182,157,466 shares outstanding as of March 31, 2026 plus the 5,790,453 conversion shares added under Rule 13d-3(d)(1)(i). The disclosed position reflects conversion rights under a Loan and Security Agreement and an amendment; K2HV Equity may acquire the shares within 60 days upon conversion of outstanding debt obligations.
Neumora Therapeutics, Inc. reported a net loss of $53.5M for the quarter ended March 31, 2026, narrower than the prior-year period. Operating expenses fell to $52.9M as both research and development and general and administrative costs declined.
The company ended the quarter with $147.1M in cash and cash equivalents and believes this will fund operations for at least 12 months from issuance of the statements. Net cash used in operating activities was $46.4M, partly offset by $10.9M of proceeds from at-the-market stock sales.
Neumora remains a clinical-stage biotech with no product revenue, advancing multiple brain-focused programs. Its lead asset, navacaprant for major depressive disorder, is in Phase 3, with KOASTAL-2 and KOASTAL-3 topline data expected in the second quarter of 2026. Additional readouts for NMRA-511 and NMRA-898 are planned for the second half of 2026.
Neumora Therapeutics reported first quarter 2026 results, highlighting lower operating expenses and an extended cash runway as it advances its neuroscience pipeline. Research and development expenses fell to $38.6 million from $52.2 million a year earlier, while general and administrative expenses decreased to $14.3 million from $18.8 million.
Net loss narrowed to $53.5 million, compared with $68.0 million in the first quarter of 2025, with loss per share improving to $0.30 from $0.42. Neumora ended March 31, 2026 with $147.1 million in cash and cash equivalents, which it expects will fund its operating plan into the third quarter of 2027 while it progresses navacaprant, NMRA‑511, NMRA‑898 and NMRA‑215 through key clinical milestones.
Neumora Therapeutics ownership update: institutional investor group led by Invus Public Equities reports beneficial ownership stakes in the company as of March 31, 2026.
Invus Public Equities directly holds 7,740,030 shares (4.3%), Avicenna Life Sci Master Fund holds 757,792 shares (0.4%), and Raymond Debbane is reported with 8,497,822 shares (4.7%). The filing bases percentages on 182,040,945 Shares outstanding as of March 23, 2026.
Neumora Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 27, 2026 at 4:00 p.m. Eastern Time. Holders of common stock at the close of business on April 7, 2026, when 182,688,076 shares were outstanding, are entitled to vote.
Stockholders will elect three Class III directors to terms running until the 2029 annual meeting, ratify Ernst & Young LLP as independent registered public accounting firm for 2026, approve on an advisory basis the compensation of named executive officers, and choose how often to hold future advisory votes on executive pay (one, two, or three years). The Board recommends voting for all director nominees, for ratifying EY, for the say‑on‑pay resolution, and for holding say‑on‑pay votes every one year.
The proxy explains voting mechanics for stockholders of record and beneficial owners, treatment of broker non‑votes, quorum requirements, and the company’s governance structure, including board independence, key committees, and executive and director compensation programs.
ARCH Venture-affiliated funds filed Amendment No. 4 to a Schedule 13D reporting their beneficial ownership in Neumora Therapeutics, Inc. The ARCH funds report beneficial ownership of 33,847,838 shares of Common Stock, representing 18.6% of Neumora’s outstanding shares, based on 182,040,945 shares reported outstanding in the issuer’s recent annual report.
Individual reporting persons include Kristina Burow with 33,965,419 shares deemed beneficially owned (18.7%), reflecting fund interests plus personal holdings, options and restricted stock units, and Steven Gillis with 31,526,272 shares (17.3%). The group states that no reporting person has effected transactions in Neumora’s stock during the last 60 days.
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on brain and centrally mediated diseases, with multiple drug candidates across neuropsychiatric, neurodegenerative and metabolic disorders.
The lead asset, navacaprant, a kappa opioid receptor antagonist for major depressive disorder, is in the KOASTAL Phase 3 program. KOASTAL‑1 did not meet its primary endpoint, and the company optimized and fully enrolled KOASTAL‑2 and KOASTAL‑3, each with more than 400 patients, targeting a joint topline readout in the second quarter of 2026.
NMRA‑511, a V1a receptor antagonist for agitation in Alzheimer’s disease, showed clinically meaningful Phase 1b results, with multiple ascending dose data expected in the second half of 2026 and a Phase 2 trial planned for the first quarter of 2027. NMRA‑898, an M4 positive allosteric modulator for schizophrenia, is in a multiple ascending dose Phase 1 study with data expected in the second half of 2026.
NMRA‑215, a brain‑penetrant NLRP3 inhibitor for obesity, produced up to 19% weight loss as monotherapy and 26% in combination with semaglutide in diet‑induced obesity mouse studies but encountered unexpected findings in a 13‑week rat toxicology study. Neumora is repeating that study and now expects first‑in‑human trials in the first quarter of 2027.
The company also advances preclinical CK1δ and GCase programs for ALS and Parkinson’s disease and reports control of a large intellectual property estate, with over 400 owned, co‑owned, or exclusively licensed patents and applications as of December 31, 2025. The aggregate market value of common stock held by non‑affiliates was approximately $63.3 million as of June 30, 2025, and 182,040,945 common shares were outstanding as of March 23, 2026.
Neumora Therapeutics reported fourth-quarter and full-year 2025 results alongside major pipeline updates. The company recorded a Q4 2025 net loss of $59.4 million and a full-year 2025 net loss of $236.9 million, reflecting continued investment in R&D-led growth.
Research and development expenses were $176.1 million in 2025, down from $200.9 million in 2024, while general and administrative expenses eased to $60.1 million. Neumora ended 2025 with $182.5 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the third quarter of 2027.
Pipeline news included new Phase 1b data for NMRA-511 in Alzheimer’s disease agitation showing effect sizes up to 0.51 on agitation measures, with a Phase 2 study planned for Q1 2027. The KOASTAL-2 and -3 navacaprant studies are fully enrolled with a joint topline readout expected in Q2 2026. Neumora named NMRA-898 its lead M4 program for schizophrenia based on promising Phase 1 data, and highlighted positive obesity data for NMRA-215 while repeating a 13-week rat toxicology study, now targeting clinical entry in Q1 2027.
Neumora Therapeutics, Inc. officer Aurora Daljit Singh reported an open-market sale of 6,165 shares of common stock on February 17, 2026 at an average price of $3.555 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to vesting restricted stock units. After this transaction, Singh directly owned 82,770 common shares.
Neumora Therapeutics President Joshua Pinto reported a Form 4 showing the sale of 5,967 shares of common stock at $3.535 per share on February 17, 2026. According to the footnote, the shares were sold solely to satisfy tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, Pinto directly holds 57,783 shares, and an additional 152,167 shares are held indirectly by Maple DE Holdings LLC.